Internal medicine journal
-
Internal medicine journal · Jan 2023
Symptom persistence and recovery among COVID-19 survivors during a limited outbreak in Canterbury, New Zealand: a prospective cohort study.
In Canterbury, near complete identification of coronavirus disease 2019 (COVID-19) cases during a limited outbreak provides unique insights into sequelae. ⋯ Persistent symptoms and longer recovery times were found in COVID-19 survivors, but not impaired generalised anxiety levels or HrQoL compared with COVID-19-uninfected participants.
-
Internal medicine journal · Jan 2023
Comparative StudyThe same but different: a comparison of Staphylococcus aureus bloodstream infections in metropolitan and non-metropolitan hospitals (2010-2020).
Variation of infection rates between hospitals must be identified; differences may highlight opportunities for quality improvement in healthcare delivery to specific hospitals groups. ⋯ To reduce risks for SABSI and improve patient outcomes, hospital infection prevention and control programmes should be tailored according to local epidemiology. In common geographic locations, networking of hospitals should be considered as a means of strengthening delivery of these programmes.
-
Internal medicine journal · Jan 2023
A clinical scoring approach for detection of histiocytic necrotizing lymphadenitis in adults.
Histiocytic necrotising lymphadenitis (HNL) is rare and can be easily ignored. ⋯ The present study suggests that the novel scoring approach we put forward might be useful to detect HNL in adult patients though further studies are needed.
-
Internal medicine journal · Jan 2023
ANZTCT Position Statement: COVID-19 Management in Haematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T cell Patients.
Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.
-
Internal medicine journal · Jan 2023
Penicillin Allergy Delabeling Program: an exploratory economic evaluation in the Australian context.
Internationally, clinical and economic advantages of low-risk penicillin delabelling have been explored, supporting changes to healthcare delivery systems where penicillin delabelling is embedded into inpatient usual care. ⋯ Consistent with international literature, delabelling low-risk penicillin allergies in the inpatient setting had economic advantages in the Australian context. Fully powered economic evaluations are urgently required to consolidate these findings.